Abstract
Sodium glucose transporter-2 inhibitors (SGLT2-i) are a class of medicine that have been recently acknowledged and approved for management of Type-2 Diabetes Mellitus (T2DM). They have distinct encouraging extra-pancreatic glucuretic role that has been clinically applied for blood sugar management. Reports have been published for multiple side effects including ketoacidosis & ketonuria induced by SGLT2-i. This endeavor delves into the pharmacokinetics of SGLT-i agents, deliberates the utility of these drugs and suggests steps to maximize the safe use of these agents including their diverse beneficial effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
